Search
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalCYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
DG041
go.drugbank.com/drugs/DB05027ExperimentalDG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of th...
Terevalefim
go.drugbank.com/drugs/DB16397InvestigationalTerevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
KBP-COVID-19
go.drugbank.com/drugs/DB15858InvestigationalAs of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. MKC1106-PP...
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...
Huperzine B
go.drugbank.com/drugs/DB03348ExperimentalHuperzine B is a novel acetylcholinesterase inhibitor.
Lefradafiban
go.drugbank.com/drugs/DB04863InvestigationalLefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.